Optimizing Lyophilized mRNA Lipoplex Transfection: Disaccharide and Lipid Structure Effects

Study Background and Research Question

RNA-based therapeutics, particularly messenger RNA (mRNA), have transformed the landscape of gene modulation due to their programmability and transient expression. Despite the success of mRNA vaccines in recent years, further innovation is needed to address persistent challenges in mRNA delivery and transfection. Notably, efficient and reproducible delivery of mRNA to target cells is complicated by the diversity of both mRNA constructs and carrier systems. Among delivery vehicles, cationic liposome-mRNA complexes (lipoplexes) are widely studied for their simplicity and efficiency, but their formulation stability and transfection consistency remain critical obstacles. The referenced study by Shimizu and Hattori (DOI:10.3892/etm.2025.12989) addresses the practical bottlenecks in high-throughput mRNA transfection workflows. Specifically, the authors investigate how disaccharide cryoprotectants and cationic lipid structure impact the stability and efficacy of lyophilized mRNA lipoplexes in a reverse transfection format. Their work aims to inform robust protocols for screening mRNA delivery efficiency and protein function in vitro.

Key Innovation from the Reference Study

The central innovation of the study lies in its systematic evaluation of solid-phase reverse transfection using lyophilized mRNA lipoplexes in multi-well plates. Unlike conventional forward transfection, where lipoplexes are freshly prepared and added to pre-seeded cells, the reverse approach enables simultaneous cell seeding and transfection by pre-coating plates with dried complexes. This simplifies handling, reduces time, and is amenable to automation and large-scale screening, a significant advantage for evaluating multiple mRNA/lipid formulations in parallel. Importantly, the study highlights how the choice of disaccharide (trehalose or sucrose) and its concentration, as well as the structural class of the cationic lipid (dialkyl vs. trialkyl), directly influence both the preservation of lipoplex integrity during lyophilization and the subsequent mRNA delivery and transfection efficiency.

Methods and Experimental Design Insights

Shimizu and Hattori prepared mRNA lipoplexes using five types of cationic lipids—spanning dialkyl and trialkyl structures—and subjected them to lyophilization in the presence of either trehalose or sucrose at varying concentrations. These complexes were applied to multi-well plates and freeze-dried, resulting in transfection-ready solid-phase surfaces. For reverse transfection, cell suspensions were directly seeded onto the coated plates, allowing the rehydrated lipoplexes to interact with cells and facilitate mRNA delivery. The study systematically varied key parameters:

• Cationic lipid type: dialkyl vs. trialkyl cationic lipids
• Disaccharide type and concentration: trehalose or sucrose, at concentrations up to 150 mM
• Lyophilization workflow: application and drying in multi-well plate format
• Evaluation timepoints: immediate and after one month storage at room temperature

Transfection efficiency was quantified via reporter gene expression, and stability was assessed by measuring retained transfection activity after storage.

Protocol Parameters

• Disaccharide concentration: Use 150 mM sucrose during lyophilization for maximal preservation of mRNA lipoplex activity and enhanced transfection efficiency (reference study).
• Lipid selection: Prefer dialkyl cationic lipids for robust retention of transfection activity post-lyophilization; avoid trialkyl cationic lipids if maximal activity is required.
• Reverse transfection setup: Plate lyophilized mRNA lipoplexes in multi-well format; add fresh cell suspension directly to initiate transfection.
• Stability window: Lyophilized mRNA lipoplexes in 150 mM sucrose are stable for up to one month at room temperature without substantial loss of activity.

Core Findings and Why They Matter

The study demonstrates several key findings:

• Disaccharide-Dependent Enhancement: Increasing disaccharide (trehalose or sucrose) concentration during lyophilization markedly enhances transfection activity of mRNA lipoplexes. Sucrose at 150 mM provided the best preservation, supporting higher gene expression upon rehydration and transfection.
• Lipid Structure-Dependent Effects: Dialkyl cationic lipids retained transfection activity after lyophilization, whereas trialkyl cationic lipid-based lipoplexes showed significant declines. This suggests that lipid architecture plays a critical role in maintaining the functional integrity of lipoplexes through the drying and storage process.
• Long-term Stability: Lyophilized mRNA lipoplexes formulated with 150 mM sucrose were stable at room temperature for at least one month, maintaining transfection efficacy. This enables batch preparation and stocking of transfection-ready plates, facilitating high-throughput and reproducible assays.

These findings streamline the mRNA delivery and transfection workflow, reducing the requirement for immediate, labor-intensive preparation and enabling more systematic evaluation of delivery variables. The solid-phase reverse transfection approach also supports automation and scalability, which are critical for screening large libraries of mRNA or carrier formulations.

Comparison with Existing Internal Articles

Several internal resources provide complementary perspectives on optimizing mRNA delivery and expression. For example, the article "Translational Breakthroughs in mRNA Research" discusses how innovations such as Cap1 capping, 5-moUTP modification, and Cy5 labeling in synthetic mRNA constructs (e.g., EZ Cap Cy5 Firefly Luciferase mRNA) further enhance translation efficiency and minimize innate immune activation. These molecular design strategies address challenges similar to those tackled by Shimizu and Hattori, particularly regarding mRNA stability and immune response suppression during delivery (innate immune activation suppression). Another detailed review, "EZ Cap Cy5 Firefly Luciferase mRNA: Advanced mRNA Delivery", highlights the integration of dual bioluminescent and fluorescent modalities, facilitating both translation efficiency assays and real-time tracking of mRNA delivery and transfection. These internal articles expand on how formulation and chemical modification—beyond physical stabilization by disaccharides—play a central role in optimizing mRNA research workflows. In summary, while the reference paper emphasizes physical and compositional factors influencing lyophilized mRNA lipoplex performance, internal resources underscore the complementary impact of mRNA engineering and molecular labeling, providing a holistic framework for maximizing gene expression outcomes.

Limitations and Transferability

Although the study delivers actionable insights, several limitations merit consideration:

• The experiments focused exclusively on in vitro multi-well plate systems, and findings may not directly extrapolate to in vivo settings where physiological barriers and immune responses differ.
• Only a single model mRNA and a defined set of lipids/disaccharides were tested, so generalizability to other mRNA sequences or carrier systems requires further validation.
• The study did not directly address the impact of chemical modifications (e.g., 5-moUTP) or capping structures, which are increasingly recognized as critical for translation efficiency and innate immune activation suppression—topics covered in the aforementioned internal articles.
• Potential interactions between mRNA modifications and lyophilization protocols remain an open question for future research.

Despite these constraints, the described protocol parameters and workflow innovations offer a practical template for high-throughput mRNA delivery and transfection screening.

Why this cross-domain matters, maturity, and limitations

The implementation of solid-phase reverse transfection for lyophilized mRNA lipoplexes bridges the gap between basic formulation science and applied high-throughput screening in gene therapy and mRNA vaccine development. While the reference study demonstrates technological maturity for in vitro applications, translation to in vivo or clinical settings will require further optimization, especially incorporating advanced mRNA chemistries and addressing biological barriers.

Research Support Resources

To facilitate similar high-throughput mRNA delivery and translation efficiency assays, researchers may consider using EZ Cap™ Cy5 Firefly Luciferase mRNA (5-moUTP) (SKU R1010) from APExBIO. This reagent combines a Cap1 structure, 5-moUTP modification, and Cy5 fluorescent labeling, supporting both bioluminescence and fluorescence-based readouts. Its design aligns well with protocols requiring robust mRNA stability, minimized innate immune activation, and dual-mode detection, as described in the reference study. For best results, follow established lyophilization and transfection protocols, and consult product documentation for storage and handling guidance.